That stems in part from experience with an earlier weight-loss drug from Sanofi called Acomplia/Zimulti (rimonabant), which was approved in Europe in 2006, but withdrawn from sale two years later ...

Shares of the Paris-based drug giant have fallen about 9% since July 2006 because of concerns about generic competition and delays in the launch of its anti-obesity product, Acomplia. But a rich ...

Safety issues that led to the withdrawals of the cannabinoid receptor antagonist Acomplia (rimonabant) and, before that, appetite suppressant Redux (dexfenfluramine), mean that novel products are ...

This culminated in the approval of Sanofi’s Acomplia (rimonabant) in 2006 for the treatment of obesity, and the large number of clinical trials in non-alcoholic steatohepatitis (NASH), pre ...